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Eindhoven, Rotterdam, Maastricht, and Zwolle, the Netherlands; and Aalst, Belgium
Objectives The purpose of this study was to investigate the appropriateness of stenting a functionally nonsignificant
stenosis.
Background Percutaneous coronary intervention (PCI) of an intermediate stenosis without evidence of ischemia is often per-
formed, but its benefit is unproven. Coronary pressure-derived fractional flow reserve (FFR) is an invasive index
used to identify a stenosis responsible for reversible ischemia.
Methods In 325 patients scheduled for PCI of an intermediate stenosis, FFR was measured just before the planned inter-
vention. If FFR was 0.75, patients were randomly assigned to deferral (Defer group; n  91) or performance
(Perform group; n  90) of PCI. If FFR was 0.75, PCI was performed as planned (Reference group; n  144).
Clinical follow-up was 5 years.
Results There were no differences in baseline clinical characteristics between the 3 groups. Complete follow-up was ob-
tained in 98% of the patients. Event-free survival was not different between the Defer and Perform groups (80%
and 73%, respectively; p  0.52), but was significantly worse in the Reference group (63%; p  0.03). The com-
posite rate of cardiac death and acute myocardial infarction in the Defer, Perform, and Reference groups was
3.3%, 7.9%, and 15.7%, respectively (p  0.21 for Defer vs. Perform group; p  0.003 for the Reference vs.
both other groups). The percentage of patients free from chest pain at follow-up was not different between the
Defer and Perform groups.
Conclusions Five-year outcome after deferral of PCI of an intermediate coronary stenosis based on FFR 0.75 is excellent.
The risk of cardiac death or myocardial infarction related to this stenosis is 1% per year and not decreased by
stenting. (J Am Coll Cardiol 2007;49:2105–11) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.087a
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It is generally accepted that revascularization of
a coronary stenosis responsible for reversible
ischemia is justified as it relieves anginal com-
plaints, and in some situations improves patient
outcome (1–6).
In today’s interventional practice, however, a
tenosis not clearily responsible for symptoms is often
tented, even if ischemia cannot be attributed to the lesion
rom the *Catharina Hospital Eindhoven, Eindhoven, the Netherlands; †Cardiovascu-
ar Center Aalst, Aalst, Belgium; ‡Thoraxcentrum Rotterdam, Rotterdam, the
etherlands; §Academic Hospital Maastricht, Maastricht, the Netherlands; and
Isala Clinics Zwolle, Zwolle, the Netherlands. This study was supported by an
nrestricted grant from Radi Medical System, Uppsala, Sweden and the Friends of the
eart Foundation (Stichting Vrienden van het Hart), Eindhoven, the Netherlands.i
Manuscript received October 4, 2006; revised manuscript received January 29,
007, accepted January 30, 2007.nd even if it is only of mild or moderate severity (7,8). This
pplies to either a single intermediate stenosis or to an
ntermediate stenosis found incidentally in a patient under-
oing stenting because of a more severe stenosis elsewhere
n the coronary arteries.
Not only is this approach not evidence-based, but it is
lso unnecessarily expensive and might even be harmful
ecause the risk of periprocedural myocardial infarction or
ubacute stent thrombosis is not negligible, even when
rug-eluting stents are used (9,10). It is unlikely that
tenting a hemodynamically nonsignificant stenosis will
mprove complaints, and there are no data suggesting that it
ill improve patient prognosis. Defining the hemodynamic
ignificance of a stenosis from the angiogram is difficult
11). In contrast, fractional flow reserve (FFR) is an accurate
nvasive index to determine in the catheterization laboratory
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PCI of Nonsignificant Stenosis May 29, 2007:2105–11whether an angiographically
equivocal stenosis is of functional
significance (i.e., responsible for
reversible ischemia) (2,12,13).
Fractional flow reserve can be sim-
ply and rapidly determined just
before the planned intervention or
during routine diagnostic catheter-
ization. Fractional flow reserve ex-
presses maximum achievable blood
flow to the myocardium supplied
by a stenotic artery as a fraction of
ormal maximum flow. Its normal value is 1.0, and a value of
.75 identifies stenosis associated with inducible ischemia with
high diagnostic accuracy (2,12,13). Although initially applied
redominantly in patients with single-vessel disease, FFR has
ore recently been validated in many other clinical and
ngiographic conditions such as multivessel disease, previous
yocardial infarction, and left main disease (13–19).
Several studies have suggested that FFR-based decision-
aking about revascularization of an intermediate coronary
tenosis results in an excellent short-term outcome (18–20).
o date, no long-term outcome data are available.
The prospective, randomized DEFER study was under-
aken in patients with stable chest pain and a functionally
onsignificant coronary stenosis to investigate if percutane-
us coronary intervention (PCI) of such stenosis is justified.
he 2-year follow-up in these patients has been published
arlier (18). The 5-year follow-up of this study is the subject
f the present report.
ethods
tudy design and participants. The international multi-
enter prospective and randomized DEFER study was
erformed in 12 hospitals in Europe and 2 hospitals in Asia
etween June 1997 and December 1998.
Patients were eligible if they fulfilled the following
nclusion criteria: 1) referral for elective PCI of a single
ngiographically significant de novo stenosis (more than 50%
iameter stenosis by visual assessment) in a native coronary
rtery with a reference diameter of more than 2.5 mm; and 2)
o evidence of reversible ischemia had been documented by
oninvasive testing within the last 2 months.
Thus, noninvasive tests were either negative, inconclu-
ive, or simply not performed. Patients with a total occlu-
ion of the target artery, acute Q-wave infarction, or
nstable angina documented by transient ST-segment ab-
ormality were excluded. Patients with small-sized target
rteries (reference diameter 2.5 mm) were excluded be-
ause these patients have less benefit from PCI and their
nclusion could bias the outcome in favor of deferral of PCI.
here were no further exclusion criteria. The study protocol
as approved by the institutional review boards of all the
articipating centers, and written informed consent was
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
FFR  fractional flow
reserve
PCI  percutaneous
coronary intervention
SPECT  single-photon
emission computed
tomographybtained by all patients before entering the study.andomization procedure. Figure 1 depicts the flowchart
f the study. Immediately after inclusion in the study and
efore any physiologic measurement was performed, pa-
ients were randomized to deferral or performance of PCI.
ext, FFR was determined (see the following text). If FFR
as 0.75, the randomization was ignored because such
FR reveals clear evidence of ischemia, PCI is of proven
enefit, and it was considered unethical not to stent these
esions (3,4,20).
On the contrary, if the FFR was 0.75, making it
nlikely that the stenosis was responsible for anginal com-
laints or reversible ischemia, the randomization was exe-
uted, resulting in 1 group of patients with an FFR 0.75
n whom PCI was deferred and treated medically, and 1
roup of patients with an FFR0.75 in whom stenting was
erformed despite the fact that their stenosis was most likely
ot of functional significance.
This resulted in 3 groups of patients: 1) patients with an
FR 0.75 in whom PCI was deferred (Defer group); 2)
atients with an FFR 0.75 in whom PCI was performed
Perform group); and 3) patients with an FFR 0.75 in
hom PCI was performed anyway as originally planned
Reference group).
The reason behind this randomization scheme was to
void any selection bias in favor of the Defer group. Firstly,
f the FFR would have been determined before the random-
zation, there would have been a chance that an operator
ould not include a patient in the study because the FFR
easurement did not fit with his visual interpretation or
ntuition of what would be the best treatment. Secondly,
Figure 1 Flowchart of the Study,
Randomization, and Definition of the 3 Groups
To avoid bias, randomization was performed before the physiologic measure-
ment (see text). DEFER  deferral of percutaneous coronary intervention;
FFR  fractional flow reserve; PCI  percutaneous coronary intervention;
PERFORM  performance of percutaneous coronary intervention; REFER-
ENCE  percutaneous coronary intervention anyway because of ischemic frac-
tional flow reserve.
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May 29, 2007:2105–11 PCI of Nonsignificant Stenosishis randomization protocol accounted for possible compli-
ations related to the performance of the pressure measure-
ent itself. Thirdly, in this way the unique opportunity was
btained to compare outcome in a group of patients with an
schemic stenosis (Reference group) with a group of patients
ith a stenosis of similar angiographic severity but not
unctionally significant (Defer and Perform groups).
uantitative angiography. After administration of 200 g
f intracoronary nitroglycerine, angiography was performed
n at least 2 orthogonal projections both before the proce-
ure and after PCI was performed. All angiograms were
nalyzed by using the QCA-CMS system (Medis, Leiden,
he Netherlands). Using the guiding catheter as a scaling
evice, reference diameter, minimal lumen diameter, and
ercent diameter stenosis were calculated as the mean of the
alues obtained from the 2 projections (21).
oronary pressure measurement and calculation of FFR.
fter eligibility was established and immediately after cor-
nary angiography, patients were randomized as described
hereafter coronary pressure was measured using a 0.014-
nch sensor-tipped PCI guidewire (PressureWire, Radi
edical Systems, Uppsala, Sweden). The wire was intro-
uced through a 6- or 7-F guiding catheter, calibrated,
dvanced into the coronary artery, and positioned distal to
he stenosis as previously described (12,13). Adenosine was
dministered to induce maximum hyperemia, either intra-
enously (140 g/kg/min) or intracoronary (15 g in the
ight or 20 g in the left coronary artery) (12,22).
Fractional flow reserve was calculated as the ratio of mean
yperemic distal coronary pressure measured by the pressure
ire to mean aortic pressure measured by the guiding
atheter. The measurement was performed twice, and FFR
as taken as the average of both measurements.
Next, PCI was performed in the patients in the Perform
nd Reference groups, according to local routine of the
articipating centers. The study was performed in 1997 and
998, and, therefore, as a matter of fact, only bare-metal
tents were used. Coronary pressure measurement after
tenting was not allowed, and evaluation of the result of
tenting was performed according to the regular routine in
he participating centers.
nd points and follow-up. Clinical follow-up was per-
ormed at hospital discharge and after 1, 3, 6, 12, 24, and 60
onths.
The primary end point (outcome) was freedom from
dverse cardiac events after 2 years of follow-up. The 5-year
ollow-up was a secondary end point but is the primary
ocus of this paper. Adverse cardiac events were defined as
ll-cause mortality, myocardial infarction, coronary artery
ypass grafting, and coronary angioplasty. Cardiac mortality
as defined as any death not clearly attributable to a
oncardiac cause. An independent end points committee
eviewed all events, and analysis was based on the commit-
ee’s adjucation.
Myocardial infarction was defined as a clinical episode of
ypical chest pain with development of new pathologic mwaves on the electrocardiogram or an increase of serum
reatinine kinase levels to more than twice the normal value
23,24).
The other secondary end points (quality of life) included
reedom from angina (Canadian Cardiovascular Society
lass I) at 1, 3, 6, 12, 24, and 60 months of follow-up and
he usage of antianginal drugs.
Repeated angiography was only performed if clinically
ndicated or in case of an adverse event. Decision on further
reatment and medications during follow-up were entirely
eft to the discretion of the referring cardiologist.
tatistical analysis. All comparisons were made on an
ntention-to-treat basis. Continuous variables are described
s mean value  1 SD, whereas dichotomous variables are
escribed as numbers and percentages. Differences in base-
ine characteristics between patients in the different groups
ere analyzed by unpaired Student t tests (continuous data)
r chi-square tests (dichotomous data).
Patient’s survival curves for absence of adverse cardiac
vents were constructed accorded to the method of Kaplan
nd Meier and compared by the log-rank test. A p value of
0.05 was considered significant; all tests were 2-tailed.
esults
aseline characteristics and procedural results. Out of
25 patients, 167 were randomly assigned to deferral and
58 to performance of PCI (Fig. 1). Baseline characteristics
f patients of both randomization arms, including angio-
raphic characteristics and FFR, were similar (Table 1).
Fractional flow reserve was 0.75 in 181 patients of
hom 91 belonged to the group randomized to deferral of
aseline Characteristicsf the Patients in the 3 Groups
Table 1 Baseline Characteristicsof the Patients in the 3 Groups
FFR >0.75 FFR <0.75
Defer Group
(n  91)
Perform Group
(n  90)
Reference Group
(n  144)
Age (yrs) 61 9 61 11 60 9
Gender (%)
Male 65 63 80
Female 35 37 20*
Risk factors (%)
Diabetes 15 9 13
Hypertension 36 34 42
Hyperlipidemia 43 48 49
Current smoker 27 23 29
Family history of CAD 56 46 45
Ejection fraction (%) 67 9 67 10 68 9
Angiography
Reference diameter (mm) 3.00 0.64 2.94 0.57 2.97 0.58
DS (%) 48 9 48 10 57 12*
MLD (mm) 1.55 0.37 1.50 0.36 1.28 0.39*
Lesion length (mm) 9.8 5.4 10.2 4.3 9.5 3.9
FFR 0.87 0.07 0.87 0.06 0.56 0.16*
p  0.05 for comparison between Defer and Perform groups versus Reference group.
CAD  coronary artery disease; DS  diameter stenosis; FFR  fractional flow reserve; MLD 
inimum luminal diameter.
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PCI of Nonsignificant Stenosis May 29, 2007:2105–11CI (Defer group) and 90 to the group randomized to
erformance of PCI (Perform group). Fractional flow re-
erve was 0.75 in 144 patients. In the latter group
Reference group), randomization was ignored and PCI
erformed anyway. The angiographic stenosis severity in
hese 3 groups is presented in Figure 2.
Average percent diameter stenosis was more severe in the
eference group (FFR 0.75). However, overlap of data
as so large that quantitative coronary angiography was
bsolutely not useful for predicting the true stenosis severity
n individual patients.
Fractional flow reserve was 0.86  0.06 in the Defer
roup, 0.87  0.07 in the Perform group, and 0.57  0.16
n the Reference group. The absolute difference between the
rst and second FFR measurement was 0.03  0.02.
Finally, all angiographic parameters after PCI were sim-
lar in the Perform and Reference groups, indicating that no
ifference was present in the quality of stenting.
n-hospital adverse events. Table 2 shows the in-hospital
dverse events. None of the patients in the Defer group had
n in-hospital event. In the Perform group, 5 patients
5.5%) had an in-hospital event (p  0.03 for comparison
ith the Defer group). In the Reference group, 12 patients
8.3%) experienced an in-hospital event (no difference with
he Perform group, p  0.61; p  0.004 for comparison
ith the Defer group).
ong-term follow-up. Complete follow-up was obtained
n 325 patients (100%) after 12 months, in 317 patients
98%) after 24 months, and in 313 patients (97%) after 5
ears.
In Figure 3, the Kaplan-Meier curves of the 3 groups are
resented. At first, it can be noted that despite PCI,
vent-free survival in patients with a functionally significant
tenosis (Reference group, FFR 0.75) was significantly
Figure 2 Stenosis Severity at Baseline Assessed by
Quantitative Coronary Angiography in the 3 Groups
Abbreviations as in Figure 1.tower than in patients with a functionally nonsignificant
tenosis (61% vs. 76%; p  0.03). Secondly, in the patients
ith a functionally nonsignificant stenosis (FFR 0.75),
vent-free survival was significantly higher irrespective of
hether the stenosis was stented or not. Event-free survival
f 5 years in the Defer group was 79% and in the Perform
roup 73% (p  0.52).
Of all cardiac events, 67%, 70%, and 72%, respectively,
ould be attributed to the index stenosis in the Defer,
erform, and Reference groups. The different events are
pecified in Table 2.
The proportion of patients experiencing cardiac death or
cute myocardial infarction (AMI) after 5 years is presented
n Figure 3, middle panel. For patients with a functionally
ignificant stenosis that was treated by PCI, the rate of
ardiac death or AMI was more than 5 times higher than in
atients with a similar angiographic but functionally non-
ignificant stenosis that was treated medically (p  0.002).
However, the prognosis of a functionally nonsignificant
tenosis was excellent anyway, and, if treated medically, the
ate of death or AMI related to that stenosis was 1% per
ear and not decreased by PCI (Table 2, Fig. 3).
unctional class and use of medication. Figure 3, bottom
anel, shows the percentage of patients free from angina at
ollow-up. This percentage increased significantly in all
roups after the index procedure, and this increase persisted
n-Hospital Events andumulative Events After 5 Years
Table 2 In-Hospital Events andCumulative Events After 5 Years
FFR >0.75 FFR <0.75
Defer Group
(n  91)
Perform Group
(n  90)
Reference Group
(n  144)
In-hospital events, n (%) 0 5 (5.5) 12 (8.3)
Death 0 0 0
Q-wave MI 0 1 (1.1) 3 (2.1)
Non–Q-wave MI 0 2 (2.2) 6 (4.2)
CABG 0 0 3 (2.1)
(Re)-PCI 0 1 (1.1) 1 (0.7)
Other serious events 0 1 (1.1) 2 (1.4)
Events after 5 yrs, n (%)
Lost to follow-up 1 (1.1) 2 (2.2) 10 (6.9)
Cardiac death 3 (3.3) 2 (2.3) 8 (6.0)
Noncardiac death 3 (3.3) 3 (3.4) 4 (3.0)
Q-wave MI 0 4 (4.5) 6 (4.5)
Non–Q-wave MI 0 2 (1.1) 7 (5.2)
CABG 1 (1.1) 4 (4.5) 14 (10.4)
TVR 8 (8.9) 8 (9.1) 18 (13.4)
Non-TVR 6 (6.7) 6 (6.8) 11 (8.2)
Other 0 1 (1.1) 2 (1.5)
Total events after 5 yrs, n (%) 21 30 70
Patients with 1 event 19 (21) 24 (27) 52 (39)*
Patients free of chest pain 61 (67) 51 (57) 104 (72)†
p  0.03 as compared to both other groups; †p  0.028 as compared to both other groups;
 0.015 compared to the Perform group.
CABG  coronary artery bypass surgery; FFR  fractional flow reserve; MI  myocardial
nfarction; PCI  percutaneous coronary intervention; TVR  target vessel revascularization.hroughout the study.
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May 29, 2007:2105–11 PCI of Nonsignificant StenosisThe improvement in anginal status was most pronounced
n the Reference group (i.e., the patients with a stenosis able
o induce myocardial ischemia) thereby confirming the
unctional benefit of performing PCI in these patients (p 
.001 at 1 month, 1 year, and 2 years, and p  0.028 at
years).
In the patients with a functionally nonsignificant stenosis,
here was also significant benefit in terms of anginal class,
rrespective of whether the stenosis was stented or not. At
years, there was even a significant benefit in favor of the
efer group (p  0.021).
Use of antianginal medication and lipid-lowering drugs
as similar in all 3 groups, both at baseline, during, and at
he end of the study (Table 3). Aspirin was used by the vast
ajority of patients during the study (Table 3). Clopidogrel
as not a standard drug when the study started and not used
t that time, but was started during the course of the study
y a number of patients undergoing re-PCI (i.e., after an
nd point had been reached).
iscussion
rom the present study, 2 important conclusions can be
rawn. First, PCI of a functionally nonsignificant stenosis
i.e., not responsible for reversible ischemia), as indicated by
n FFR0.75, is not of benefit for the patient, neither from
prognostic nor from a symptomatic point of view. There-
ore, PCI of such stenosis should be discouraged.
Secondly, the lesions at greatest risk of causing cardiac
eath or AMI are those that are functionally significant as
dentified by an FFR0.75. Even when treated by PCI, the
hance of dying or experiencing an AMI related to such a
tenosis in the next 5 years is 5 times higher than for a
tenosis of similar angiographic severity but not associated
ith reversible ischemia and treated medically.
In fact, these observations are in line with earlier nonin-
asive studies by MIBI single-photon emission computed
se of Antianginal and Lipid-Lowering Medication
Table 3 Use of Antianginal and Lipid-Lowering Medication
FFR >0.75 FFR <0.75
Defer Group Perform Group Reference Group
Use at baseline (%) n 91 n 90 n 144
Beta-blockers 71 62 61
Calcium-channel blockers 43 47 44
Nitrates 56 53 58
Use of any antianginal drug 87 83 88
Statins 37 37 35
Aspirin 92 92 95
Use at 5 yrs (%) n 84 n 83 n 122
Beta-blockers 55 53 56
Calcium-channel blockers 38 38 37
Nitrates 41 39 32
Use of any antianginal drug 63 64 65
Statins 73 73 72
Aspirin 77 86 89Figure 3 Survival and Adverse Events
(Top) Kaplan-Meier survival curves for freedom from adverse cardiac events
during 5 years follow-up for the 3 groups. (Middle) Cardiac death and acute
myocardial infarction rate in the 3 groups after a follow-up of 5 years. (Bottom)
Percentage of patients free from chest pain in the 3 groups at baseline and
during follow-up. *p  0.028; **p  0.001; ***p  0.021. MI  myocar-
dial infarction; other abbreviations as in Figure 1.FR  fractional flow reserve.
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PCI of Nonsignificant Stenosis May 29, 2007:2105–11omography (SPECT) in large numbers of patients indicat-
ng that the most important prognostic factor in patients
ith coronary artery disease is the presence and extent of
nducible ischemia (25–29).
The incidence of angiographically visible coronary artery
isease increases with age and is at least 40% in a 60-year
ld population (30). Therefore, when angiography is per-
ormed without previous evidence of ischemia, it is not
bvious that any abnormality seen at subsequent angiogra-
hy is responsible for reversible ischemia. This issue is even
ore relevant today, with an increasing number of patients
ith multivessel disease, where often 1 or more equivocal,
oncomitant lesion is seen on the angiogram in addition to
or more severe stenoses for which PCI is not disputed
13,14,17,19).
Some previous studies suggested that acute ischemic
vents not infrequently occur at the site of previously
nsignificant or mild stenosis (31,32). This has been ex-
ended into the general belief that a mild stenosis could have
worse prognosis and that use of PCI in such a lesion might
e beneficial (8). However, the present study shows that
CI of such lesions without functional significance does not
mprove outcome or anginal status and does not reduce the
se of antianginal medication. In contrast, our study indi-
ates that significantly greater risk is associated with steno-
es responsible for inducible ischemia.
In this context, it should be emphasized that in our study
he total event rate in the patients of the Defer group was
1% after 5 years, which is still several times higher than in
n age-matched population without any heart disease (32).
herefore, it is obvious that the presence of a functionally
onsignificant stenosis reflects some increased risk.
However, the issue addressed here is whether the risk can
e reduced by stenting. In these patients, modifying risk
actors and adequate medical treatment are probably of
reater prognostic value than a mechanical coronary inter-
ention (33–36). The fact that acute coronary syndromes do
ot infrequently occur at the site of a nonsignificant stenosis
erely reflects the ubiquity of such plaques, not its individ-
al property for rupture.
According to the current guidelines, PCI should be
erformed after having documented inducible ischemia
1,2). Nevertheless, prior noninvasive evidence of ischemia
s present in a minority of patients undergoing PCI (7).
ractional flow reserve, calculated from coronary pressure
easurement, is a reliable, invasive index to indicate if a
tenosis is ischemia-related and can be determined in the
atheterization laboratory in a simple and rapid way (12,18–
0). In patients with multivessel disease, in whom MIBI
PECT is often less reliable for indicating the functional
ignificance of individual stenoses (37), FFR reliably inter-
ogates any individual stenosis and, therefore, can be used
or immediate decision-making in the catheterization labo-
atory whether to stent or not (14,17–19).
Our study has several limitations. In the first place, it was
erformed in an era when drug-eluting stents were not yet
Evailable. However, although drug-eluting stents do reduce
arget vessel revascularization, they do not decrease mortality or
he risk of AMI after PCI, which is still 3% to 5% in the first
ear (7,9,10,38–40). Therefore, if drug-eluting stents would
ave been available at the time of the study, target vessel
evascularization could have been lower in the Perform group,
ut the mortality and AMI rate as presented in Figure 3, would
ost likely not have been affected, and the conclusions of the
tudy would have remained unchanged in this respect.
Secondly, the majority of the patients in the DEFER
tudy had a single stenosis of uncertain functional severity in
single coronary artery. Today, patients in the catheteriza-
ion laboratory more often have multivessel disease, often
ith 1 or more angiographically severe stenoses and con-
omitant intermediate stenoses (13,14,17,19,20). Although
ome caution is warranted in extrapolating our study results
o the population of today, our study suggests that stenting
hese coincidental intermediate stenoses without measuring
FR to demonstrate their physiologic significance does not
mprove outcome and is questionable.
In the third place, our study does not provide data
egarding what the adverse cardiac event rate would have
een in the Reference group—patients with FFR0.75—if
tenting had not occurred. As explained in the introduction
nd confirmed in this study, however, stenting ischemia-
roducing lesions improves symptoms. Therefore, not per-
orming PCI in these patients was not allowed for ethical
easons (1–6). In addition, recent data indicate that not
erforming revascularization in patients with a hemodynami-
ally significant stenosis with FFR 0.75 is detrimental (20).
Finally, it should be emphasized that the DEFER study
as performed in patients with stable chest pain, and no
onclusions can be drawn for unstable coronary syndromes
ith transient electrocardiogram changes or elevated enzymes.
In conclusion, our study indicates that in patients with stable
hest pain, the most important prognostic factor of a given
oronary artery stenosis with respect to cardiac death or AMI
s its ability to produce myocardial ischemia as reflected by
n FFR 0.75. In those patients, even when treated by
CI, clinical outcome is significantly worse than in patients
ith a functionally nonsignificant stenosis (FFR 0.75).
The risk that a hemodynamically nonsignificant stenosis
ill cause death or AMI is 1% per year and is not
ecreased by stenting.
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